McLaren agrees to $7.75 million settlement on opioid drug diversion charges
Print
McLaren Health Care Corp., a 14-hospital health system based in Grand Blanc, has agreed to a $7.75 million civil settlement over the health system s handling of controlled substances in its retail pharmacy program, federal officials said Tuesday.
The settlement resolved allegations that McLaren violated certain provisions of the federal Controlled Substances Act, according to a statement from U.S. attorneys Andrew Birge in the Western Michigan District and Matthew Schneider in the Eastern Michigan District.
It ended an investigation over several years in which employees at multiple McLaren facilities in Michigan were alleged to have diverted drugs from about 2014 to 2019 and violated federal laws, officials said.
McLaren agrees to pay record $7.75M settlement over drug diversion allegations
Updated Jan 20, 2021;
Facebook Share
PORT HURON, MI McLaren Health Care Corporation will pay the United States the nation’s largest settlement of its kind for allegations of drug diversion at a health care system.
The United States Attorneys’ Offices for the Western and Eastern Districts of Michigan announced Tuesday, Jan. 19, McLaren Health Care Corporation (MHCC) agreed to pay the United States $7.75 million to resolve allegations that it violated certain provisions of the Controlled Substances Act, according to a U.S. Attorneys’ Office news release.
The government alleged that McLaren Port Huron Pharmacy and McLaren Yale Pharmacy in the Eastern District of Michigan dispensed Schedule II drugs without written prescriptions and despite “red flags” that those drugs were being diverted by the MHCC’s pharmacist who were in charge. The government further alleged that several MHCC facilitie